Sonic Healthcare Limited · ASX:SHL
Sonic Healthcare — Shareholder Meeting (November 2019)
26 slides from Sonic Healthcare's shareholder meeting presentation, Nov 19, 2019
Slide 1: Annual General Meeting
Annual General Meeting 19 November 2019
Slide 2: Forward-looking statements
Forward-looking statements This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on f
Slide 3: Headlines FY 2019
Headlines FY 2019 FY 2019 result in line with guidance (constant currency) Underlying EBITDA growth 6.7% Statutory result strong (actual currency) Revenue growth 11.6% to A$6.2 billion EBITDA growth 13.3% to A$1.1 billion Net profit growth 15.6% to A$550 million Final dividend up 4.1%
Slide 4: FY 2020 Guidance
FY 2020 Guidance FY 2020 EBITDA growth guidance confirmed after 4 months’ trading Guidance EBITDA growth 6-8% on underlying FY 2019 EBITDA of A$1,052 million (constant currency) Interest expense to decrease by ~5% (constant currency)* Effective tax rate ~25% Capital expenditure expected
Slide 5: Dividends
Dividends A$ FY 2019 FY 2018 Growth Interim Dividend $0.33 $0.32 3.1% Final Dividend $0.51 $0.49 4.1% Total Dividends $0.84 $0.81 3.7% Final dividend franked to 30% (interim dividend franked to 20%) Record date 11 September 2019 Payment date 25 September 2019 Dividend Reinvestment Plan suspe
Slide 6: Full-year Dividend
Full-year Dividend $0.90 $0.84 $0.80 $0.70 $0.60 $0.50 A$ $0.40 $0.30 $0.20 $0.10 $0.00 Financial Year Sonic Healthcare | AGM November 2019
Slide 7: Annual Revenue
Annual Revenue 7.0 6.7* 6.2 6.0 5.0 4.0 A$B 3.0 2.0 * FY 2020 revenue, including full 1.0 year of Aurora acquisition, based on market consensus forecast, 0.014 including FX rate assumptions. Illustrative only, not Sonic guidance. 0.0 Financial Year Sonic Healthcare | AGM November 2019
Slide 8: Annual Revenue: Australia v International
Annual Revenue Australia v International 7,000 6,000 5,000 4,000 Australia 39% A$M 3,000 International 61% 2,000 1,000 Australia International - Australia International Sonic Healthcare | AGM November 2019
Slide 9: International Expansion
International Expansion GERMANY SWITZERLAND BELGIUM UNITED KINGDOM IRELAND USA AUSTRALIA NEW ZEALAND Market leader #1 Sonic Healthcare | AGM November 2019
Slide 10: Acquisitions – 32 Years of Enrichment
Acquisitions – 32 Years of Enrichment Acquired companies are culturally aligned Integrations and mergers smooth Fall-out minimal Drives loyalty, commitment, passion Global unity of purpose Acquired companies add value to Sonic Adding people and talent Geographical diversification S
Slide 11: Sonic Healthcare Today
Sonic Healthcare Today International healthcare company providing laboratory, imaging and primary care services Third largest medical laboratory company in the world Top-50 ASX listed, market capitalization ~$13.5 billion Revenue A$6.2 billion p.a., EBITDA A$1.1 billion p.a. (FY 2019) Oper
Slide 12: Sonic Healthcare | AGM November 2019
Sonic Healthcare | AGM November 2019
Slide 13: Behind Every Test is a Patient
Behind Every Test is a Patient Corporate Responsibility Report 2019 Email from a long-standing shareholder: “I wanted to say how good it was, and how much of a picture it paints of the organization, beyond the financial numbers that underpin it. I enjoyed the ‘My Story’ segments and in particula
Slide 14: Pathologists
Pathologists Medical Specialists in the laboratory Medical degree – 6 years Internship/Residency – 2 years Pathologist Fellowship – 5 years Supervise testing and ensure quality in pathology laboratory Consultants to clinicians – GPs and specialists Result interpretation, diagnosis and
Slide 15: Sonic Pathology Australia
Sonic Pathology Australia National Coverage / Market Leader
Slide 16: Douglass Hanly Moir Pathology
Douglass Hanly Moir Pathology Sydney, Australia
Slide 17: Sullivan Nicolaides Pathology
Sullivan Nicolaides Pathology Brisbane, Australia
Slide 18: Sonic Healthcare Germany
Sonic Healthcare Germany National Coverage / Market leader Sonic Healthcare Germany Laboratory locations
Slide 19: Bioscientia
Bioscientia Ingelheim, Germany
Slide 20: Bioscientia
Bioscientia Ingelheim, Germany
Slide 21: Aurora Diagnostics Acquisition
Aurora Diagnostics Acquisition A seminal event in Sonic’s history Revenue ~A$430 million (~7% of Sonic’s revenues) 32 practices, 19 states, 220 pathologists >100 hospital contracts, serving ~23,000 physicians Experienced leadership team US Anatomical Pathology market ~A$20 billion p.a.
Slide 22: Aurora Diagnostics
Aurora Diagnostics Cascade Pathology Services Twin Cities Dermatopathology Portland, OR Plymouth, MN Pathology Laboratory Grand Rapids, MI Pacific Pathology Seacoast Pathology Salem, OR Exeter, NH Hallmark Pathology Pinkus Dermatopathology Cleveland Skin Pathology Medford, MA Laboratory of Monroe, M
Slide 23: Aurora Acquisition: Growth and Synergy Opportunities
Aurora Acquisition Growth and Synergy Opportunities Growth in Anatomical Pathology market Access more clinicians Access more hospitals Cross-sell from Anatomical to Clinical Pathology Centralise complex tests Strengthen databank Pathologists and Medical Leadership Sonic and Aurora pres
Slide 24: Revenue Split – FY 2019
Revenue Split – FY 2019 New Zealand Sonic Clinical A$34M Services <1% Imaging A$438M A$500M 7% Belgium 8% Australia A$146M A$1,470M 2% 24% Switzerland A$431M 7% UK & Ireland A$435M 7% USA A$1,441M Germany 24% A$1,232M 20%
Slide 25: Outlook
Outlook Company well positioned for ongoing strong growth Rich pipeline of acquisition, joint venture and contract opportunities Strong balance sheet with headroom for expansion Geographical diversification provides growth opportunities and risk mitigation Stable, experienced and dynamic g
Slide 26: Thank you
@ SONIC sy | HEALTHCARE Thank you ae De Pm
Sonic Healthcare — Shareholder Meeting (November 2019) on 6ix